Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis.

2023-02-02

Yogendrakumar, Vignan

Churilov, Leonid

Guha, Prodipta

Beharry, James

Mitchell, Peter J

Kleinig, Timothy J

Yassi, Nawaf

Thijs, Vincent N

Wu, Teddy Y

Brown, Helen

Dewey, Helen M

Wijeratne, Tissa

Yan, Bernard

Sharma, Gagan

Desmond, Patricia M

Parsons, Mark W

Donnan, Geoffrey A

Davis, Stephen M

Campbell, Bruce C V

carotid artery

reperfusion

tenecteplase

thrombus

tomography

Journal Article

0000-0001-8814-6853

0000-0002-9807-6606

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0002-4932-954X

0000-0002-8337-7529

0000-0003-4430-3276

0000-0002-0685-0060

0000-0002-6614-8417

0000-0003-1845-1769

0000-0001-9142-2708

0000-0001-9484-2070

0000-0002-1701-7111

0000-0001-8802-9606

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0002-4803-6323

0000-0001-8874-2487

0000-0001-6324-3403

0000-0003-0962-2300

0000-0003-3632-9433

10.1161/STROKEAHA.122.041061

Intracranial occlusion site, contrast permeability, and clot burden are thrombus characteristics that influence alteplase-associated reperfusion. In this study, we assessed the reperfusion efficacy of tenecteplase and alteplase in subgroups based on these characteristics in a pooled analysis of the EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke).

link

Stroke 2023; 54(3)

Stroke

1524-4628